Ironwood will focus on commercializing its currently marketed products and the development of its gastrointestinal, gout and abdominal pain pipeline. It is expected to be profitable in 2019.
Ironwood Pharmaceuticals plans to split into two independent, publicly traded companies, spinning off some of its research and development work into a yet-unnamed business in the first half of 2019.